Back to top

Image: Bigstock

The Zacks Analyst Blog Highlights: Oracle, Eli Lilly and BP

Read MoreHide Full Article

For Immediate Release

Chicago, IL – April 12, 2021 – announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Oracle Corporation (ORCL - Free Report) , Eli Lilly and Company (LLY - Free Report) and BP p.l.c. (BP - Free Report) .

Here are highlights from Friday’s Analyst Blog:

Top Stock Reports for Oracle, Eli Lilly and BP

The Zacks Research Daily presents the best research output of our analyst team. Today’s Research Daily features new research reports on 16 major stocks, including Oracle Corporation, Eli Lilly and Company, and BP p.l.c. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Shares of Oracle have gained +22.4% over the last six months against the Zacks Computer – Software industry’s gain of +9.6%. The Zacks analyst believes that Oracle is gaining from ongoing momentum witnessed across its cloud business, driven by solid adoption of data cloud solutions, Enterprise Resource Planning (ERP) and Autonomous Database offerings. Further, strong uptake of cloud-based solutions, comprising NetSuite ERP and Fusion ERP, bodes well.

Also, companies like MercadoLibre, Xactly, 8x8 and Zoom Video have selected Oracle Cloud Infrastructure services, which is a testament to the strength of its cloud offerings. However, rising spend on product enhancements amid stiff competition in the cloud market is likely to limit margin expansion.

(You can read the full research report on Oracle here >>>)

Shares of Eli Lilly have outperformed the Zacks Large Cap Pharmaceuticals industry in the year-to-date period (+8.1% vs. -0.6%). The Zacks analyst believes that Lilly’s revenue growth is being driven by higher demand for drugs like Trulicity, Taltz, and others. Lilly has some intriguing pipeline assets for cancer, diabetes and Alzheimer's that provide boost its growth potential beyond 2025. It also received rapid emergency approvals for bamlanivimab (monotherapy and combo) for COVID-19 in 2020. It is regularly adding promising new pipeline assets through business development deals. 

However, generic competition for several drugs, rising pricing pressure in the United States mainly on key drug Trulicity, and price cuts in some international markets like China, Japan and Europe are some top-line headwinds.

(You can read the full research report on Eli Lilly here >>>)

Shares of BP have increased +20.5% in the year-to-date period against the Zacks Oil and Gas - Integrated – International industry’s gain of +19.6%. The Zacks analyst believes that BP has a strong portfolio of upstream projects, which has been backing impressive production growth. Since 2016, BP has placed several key upstream projects online.

All the key projects BP has been delivering over the years backed the company to post record production levels. The company also plans to boost capital spending on renewable power business as most oil companies in Europe have decided to combat climate change by reducing greenhouse gas and carbon emissions, and focusing on clean energy.

However, the company’s significant reliance on debt capital is a concern. Hence, the firm can’t rely on its balance sheet unlike peers to combat the pandemic-induced uncertainty. Lower refinery throughput is still affecting the firm’s bottom-line.

You can read the full research report on BP here >>>)

Zacks Names “Single Best Pick to Double”

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

You know this company from its past glory days, but few would expect that it’s poised for a monster turnaround. Fresh from a successful repositioning and flush with A-list celeb endorsements, it could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in a little more than 9 months and Nvidia which boomed +175.9% in one year.

Free: See Our Top Stock and 4 Runners Up >>

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339                                                                        


Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release.

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Oracle Corporation (ORCL) - free report >>

Eli Lilly and Company (LLY) - free report >>

BP p.l.c. (BP) - free report >>